文献速递脊柱脊髓外科神经肿瘤

晚期胸椎副神经节瘤多模式治疗的系统评价与病例报告

Systematic Review and Case Report of Multimodal Therapy for Treatment of Advanced Thoracic Spine Paraganglioma.
PubMed 文献 · World Neurosurg · 2025-04-11

本文报告一例55岁男性SDHB突变转移性副神经节瘤患者,因T1-T3椎体及硬膜外病变致脊髓压迫出现进行性肢体无力,既往接受椎板切除融合术及放疗后失败,采用血管内栓塞、手术切除内固定融合、放疗及替莫唑胺化疗的多学科干预。同时对副神经节瘤合并SDHB突变患者进行系统评价,纳入14项研究共66例患者。

要点

  • SDHB突变相关副神经节瘤可表现为转移性/多灶性病变,治疗选择多样。
  • 病例采用血管内栓塞、手术切除内固定融合、放疗及替莫唑胺化疗的多模式治疗。
  • 系统评价纳入14项研究共66例副神经节瘤合并SDHB突变患者。

核心结论

  • 转移性/多灶性副神经节瘤虽罕见,但其偶尔的难治性病程可能需要复杂多学科治疗以最大化神经和肿瘤学结局。

研究设计与样本

  • 系统评价:纳入14项研究共66例副神经节瘤合并SDHB突变患者,纳入标准为副神经节瘤诊断及SDHB突变。
  • 病例报告:一例55岁男性SDHB突变转移性副神经节瘤患者。

主要发现

  • 55岁男性患者,有转移性副神经节瘤治疗史及SDHB突变,表现为进行性肢体无力。
  • 影像发现T1-T3椎体及硬膜外病变致显著脊髓压迫,该区域既往接受椎板切除融合术及放疗。
  • 因神经症状及既往放疗失败,采用血管内栓塞、手术切除内固定融合、放疗及替莫唑胺化疗治疗该病变及偶然发现的T12病变。
  • 系统评价显示副神经节瘤合并SDHB突变患者治疗选择多样。

临床怎么用

  • 作者认为,转移性/多灶性副神经节瘤偶尔呈难治性病程,可能需要复杂多学科治疗以最大化神经和肿瘤学结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Paragangliomas are rare neuroendocrine tumors that can manifest with endocrinological symptoms from excessive catecholamine secretion and symptoms from mass effect depending on biochemical behavior and tumor location. METHODS: Following an encounter with a patient with a rare case of paraganglioma of the thoracic spine, a systematic review was performed of patients with a diagnosis of paraganglioma and SDHB mutation. Inclusion criteria were met by 14 studies for a total of 66 patients. RESULTS: A 55-year-old man with a known history of treated metastatic paraganglioma with SDHB mutation presented with progressive weakness in his extremities. He was found to have significant spinal cord compression from a lesion localized to T1-T3 vertebrae with vertebral body as well as epidural involvement. This area was previously treated with laminectomy and fusion as well as radiotherapy. Given his neurological symptoms and failure of previous radiotherapy treatment, our treatment approach was aggressive multidisciplinary intervention. He successfully underwent endovascular embolization, surgical resection with instrumented fusion, radiotherapy, and chemotherapy with temozolomide to treat this lesion as well as an incidentally located T12 lesion. Given the rarity of this disease, we performed a systematic review of paraganglioma with SDHB mutation, which demonstrated a wide variety of treatment options. CONCLUSIONS: Although metastatic/multifocal paragangliomas are rare, their occasional relentless course may require complex multidisciplinary treatment to maximize neurological and oncological outcomes.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Treffy RW, Rahman M, DeGroot AL, et al. Systematic Review and Case Report of Multimodal Therapy for Treatment of Advanced Thoracic Spine Paraganglioma. World Neurosurg. 2025. PMID: 40222669. doi:10.1016/j.wneu.2025.123976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。